Sentiment-Signal
30,7
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
78.8
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Unternehmen & Branche
| Name | Evommune, Inc. |
|---|---|
| Ticker | EVMN |
| CIK | 0002044725 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 306,7 Mio. USD |
| Beta | 2,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 13,000,000 | -68,870,000 | -11.22 | 224,946,000 | 205,566,000 |
| 2025-09-30 | 10-Q | 10,000,000 | -12,475,000 | -8.07 | 84,544,000 | -183,137,000 |
| 2024-12-31 | 10-K | 7,000,000 | -66,808,000 | -45.29 | 76,055,000 | -144,237,000 |
| 2024-09-30 | 10-Q | 7,000,000 | -15,916,000 | -10.47 | -122,528,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-19 | Hopfner Robert Lorne | Director, 10% Owner | Open Market Purchase | 1,000 | 17.35 | 17,350.00 | +0,1% | |
| 2025-11-07 | LSP 7 Cooperative UA | 10% Owner | Open Market Purchase | 1,562,500 | 16.00 | 25,000,000.00 | +178,5% | |
| 2025-11-07 | Verduyn-van Weegen Felice Isabel | Director, 10% Owner | Open Market Purchase | 1,562,500 | 16.00 | 25,000,000.00 | +178,5% | |
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 92,904 | 16.00 | 1,486,464.00 | +10,6% | |
| 2025-11-07 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 1,157,096 | 16.00 | 18,513,536.00 | +132,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.